Improving immunotherapy for acute myeloid leukemia by editing immune cells
Official title: Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia
Funded at Boston Children's Hospital · NIH-10980798 · Data updated 2026-11-12
This study is looking at a new way to make immunotherapy for acute myeloid leukemia (AML) better and safer by changing donor cells so they can fight leukemia without harming healthy cells, which could lead to fewer side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 3, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $780,389 |
| NIH project number | 1R01CA286036-01A1 |
| Project ID | NIH-10980798 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are considering immunotherapy options.
✕Less likely to help
Patients with other types of leukemia or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research focuses on enhancing immunotherapy for acute myeloid leukemia (AML) by modifying donor hematopoietic stem/progenitor cells (HSPCs) to make them resistant to certain therapies while still effectively targeting leukemia cells. The approach involves using advanced genetic engineering techniques to alter specific proteins on these cells, allowing them to avoid damage to healthy cells and improve treatment outcomes. By ensuring that these modified cells can still function normally, the research aims to reduce the risk of side effects associated with current therapies. The ultimate goal is to create a safer and more effective treatment option for patients with AML.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer immunotherapy options for patients with acute myeloid leukemia.
How similar studies have gone: Previous research has shown promising results with similar genetic engineering approaches in other types of leukemia, indicating potential for success in this area as well.
Where this research is happening
-
Boston Children's Hospital
Boston, United States Active
Researchers
- Principal investigator: Genovese, Pietro — Boston Children's Hospital
- Study coordinator: Genovese, Pietro
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.